Stock Events

Stock Events

Beam Therapeutics 

$29.64
373
+$0.18+0.61% 17:07 Today

Statistics

Day High
29.97
Day Low
28.91
52W High
38.26
52W Low
18.72
Volume
566,463
Avg. Volume
2,074,207
Mkt Cap
3.06B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Mar 14
$0.23
Dec 13
$0.23
Sep 13
$0.23
Jun 13
$0.23
Mar 13
$0.23
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

9NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.24
-1.13
-1.02
-0.91
Expected EPS
-1.154044
Actual EPS
N/A

Financials

-57.24%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
139.74MRevenue
-79.99MNet Income

Analyst Ratings

58.50Average Price Target
The highest estimate is 80.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BEAM. It's not an investment recommendation.
NVIDIA
89
NVDA
Microsoft
81
MSFT
Amazon
75
AMZN
Apple
72
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a direct competitor, focusing on CRISPR/Cas9 gene editing technology, similar to Beam's base editing approach.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing space using CRISPR technology, competing in the same therapeutic areas as Beam.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in CRISPR gene editing, directly competing with Beam in developing gene-based therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, which, while a different technology, competes in the genetic disease treatment market.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, competing in the broader market of genetic disorder treatments.
Voyager Therapeutics
VYGR
Mkt Cap218.13M
Voyager Therapeutics works on gene therapy targeting severe neurological diseases, competing for similar therapeutic applications as Beam.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including gene therapies.

About

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Show more...
CEO
John Evans
Employees
540
Country
United States
ISIN
US07373V1052

Listings

BOATS
BOATS
BEAM.BOATS
XNAS
US
BEAM
MX
MX
BEAM.MX

0 Comments

Share your thoughts

FAQ

What is Beam Therapeutics stock price today?▼
The current price of BEAM is $29.64 USD — it has increased by +0.61% in the past 24 hours. Watch Beam Therapeutics stock price performance more closely on the chart.
What is Beam Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Beam Therapeutics stocks are traded under the ticker BEAM.
Is Beam Therapeutics stock price growing?▼
BEAM stock has risen by +0.9% compared to the previous week, the month change is a +4.36% rise, over the last year Beam Therapeutics has showed a +59.57% increase.
What is Beam Therapeutics market cap?▼
Today Beam Therapeutics has the market capitalization of 3.06B
When is the next Beam Therapeutics earnings date?▼
Beam Therapeutics is going to release the next earnings report on November 09, 2026.
What were Beam Therapeutics earnings last quarter?▼
BEAM earnings for the last quarter are -1.18 USD per share, whereas the estimation was -1.11 USD resulting in a -6.66% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Beam Therapeutics revenue for the last year?▼
Beam Therapeutics revenue for the last year amounts to 139.74M USD.
What is Beam Therapeutics net income for the last year?▼
BEAM net income for the last year is -79.99M USD.
Does Beam Therapeutics pay dividends?▼
Yes, BEAM dividends are paid quarterly. The last dividend per share was 0.23 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Beam Therapeutics have?▼
As of September 04, 2026, the company has 540 employees.
In which sector is Beam Therapeutics located?▼
Beam Therapeutics operates in the Health & Wellness sector.
When did Beam Therapeutics complete a stock split?▼
Beam Therapeutics has not had any recent stock splits.
Where is Beam Therapeutics headquartered?▼
Beam Therapeutics is headquartered in CAMBRIDGE, United States.